Optimal testing of the live organ donor for blood-borne viral pathogens: The report of a consensus conference

E. A. Blumberg*, M. G. Ison, T. L. Pruett, D. L. Segev

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In 2011, live donor transmission events involving Human Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) prompted consideration of changing the process of live donor testing and evaluation in the United States. Following CDC recommendations for screening all live donors with nucleic acid testing for HIV, HCV and Hepatitis B (HBV), a consensus conference was convened to evaluate this recommendation. Workgroups focused on determining whether there was an evidence based rationale for identifying live donors at increased risk for HIV, HBV and HCV, testing options and timing for diagnosing these infections in potential donors and consent issues specific to potential increased risk donor utilization. Strategies for donor assessment were proposed. Based on review of the limited available evidence as well as guidance documents and policies currently in place in the United States and other countries, the conference participants recommended that HIV, HBV and HCV NAT should not be required for live donor evaluation; the optimal timing of live donor testing for these blood borne pathogens has not been determined. The authors summarize the results of a consensus conference on testing live organ donors for HIV, hepatitis B and hepatitis C viruses.

Original languageEnglish (US)
Pages (from-to)1405-1415
Number of pages11
JournalAmerican Journal of Transplantation
Volume13
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

Blood-Borne Pathogens
Tissue Donors
Hepacivirus
HIV
Hepatitis B
Centers for Disease Control and Prevention (U.S.)
Nucleic Acids

Keywords

  • Donor infection
  • HIV
  • hepatitis B virus
  • hepatitis C virus
  • live donor transplantation
  • testing

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

@article{d994075a7c55438ab5b1fa2439a2bba9,
title = "Optimal testing of the live organ donor for blood-borne viral pathogens: The report of a consensus conference",
abstract = "In 2011, live donor transmission events involving Human Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) prompted consideration of changing the process of live donor testing and evaluation in the United States. Following CDC recommendations for screening all live donors with nucleic acid testing for HIV, HCV and Hepatitis B (HBV), a consensus conference was convened to evaluate this recommendation. Workgroups focused on determining whether there was an evidence based rationale for identifying live donors at increased risk for HIV, HBV and HCV, testing options and timing for diagnosing these infections in potential donors and consent issues specific to potential increased risk donor utilization. Strategies for donor assessment were proposed. Based on review of the limited available evidence as well as guidance documents and policies currently in place in the United States and other countries, the conference participants recommended that HIV, HBV and HCV NAT should not be required for live donor evaluation; the optimal timing of live donor testing for these blood borne pathogens has not been determined. The authors summarize the results of a consensus conference on testing live organ donors for HIV, hepatitis B and hepatitis C viruses.",
keywords = "Donor infection, HIV, hepatitis B virus, hepatitis C virus, live donor transplantation, testing",
author = "Blumberg, {E. A.} and Ison, {M. G.} and Pruett, {T. L.} and Segev, {D. L.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1111/ajt.12205",
language = "English (US)",
volume = "13",
pages = "1405--1415",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "6",

}

Optimal testing of the live organ donor for blood-borne viral pathogens : The report of a consensus conference. / Blumberg, E. A.; Ison, M. G.; Pruett, T. L.; Segev, D. L.

In: American Journal of Transplantation, Vol. 13, No. 6, 01.06.2013, p. 1405-1415.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Optimal testing of the live organ donor for blood-borne viral pathogens

T2 - The report of a consensus conference

AU - Blumberg, E. A.

AU - Ison, M. G.

AU - Pruett, T. L.

AU - Segev, D. L.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - In 2011, live donor transmission events involving Human Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) prompted consideration of changing the process of live donor testing and evaluation in the United States. Following CDC recommendations for screening all live donors with nucleic acid testing for HIV, HCV and Hepatitis B (HBV), a consensus conference was convened to evaluate this recommendation. Workgroups focused on determining whether there was an evidence based rationale for identifying live donors at increased risk for HIV, HBV and HCV, testing options and timing for diagnosing these infections in potential donors and consent issues specific to potential increased risk donor utilization. Strategies for donor assessment were proposed. Based on review of the limited available evidence as well as guidance documents and policies currently in place in the United States and other countries, the conference participants recommended that HIV, HBV and HCV NAT should not be required for live donor evaluation; the optimal timing of live donor testing for these blood borne pathogens has not been determined. The authors summarize the results of a consensus conference on testing live organ donors for HIV, hepatitis B and hepatitis C viruses.

AB - In 2011, live donor transmission events involving Human Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) prompted consideration of changing the process of live donor testing and evaluation in the United States. Following CDC recommendations for screening all live donors with nucleic acid testing for HIV, HCV and Hepatitis B (HBV), a consensus conference was convened to evaluate this recommendation. Workgroups focused on determining whether there was an evidence based rationale for identifying live donors at increased risk for HIV, HBV and HCV, testing options and timing for diagnosing these infections in potential donors and consent issues specific to potential increased risk donor utilization. Strategies for donor assessment were proposed. Based on review of the limited available evidence as well as guidance documents and policies currently in place in the United States and other countries, the conference participants recommended that HIV, HBV and HCV NAT should not be required for live donor evaluation; the optimal timing of live donor testing for these blood borne pathogens has not been determined. The authors summarize the results of a consensus conference on testing live organ donors for HIV, hepatitis B and hepatitis C viruses.

KW - Donor infection

KW - HIV

KW - hepatitis B virus

KW - hepatitis C virus

KW - live donor transplantation

KW - testing

UR - http://www.scopus.com/inward/record.url?scp=84878472440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878472440&partnerID=8YFLogxK

U2 - 10.1111/ajt.12205

DO - 10.1111/ajt.12205

M3 - Article

C2 - 23601095

AN - SCOPUS:84878472440

VL - 13

SP - 1405

EP - 1415

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 6

ER -